ALLMedicine™ Acute Lymphoblastic Leukemia Center

Feb 26th, 2021 - The use of pediatrics-inspired protocols in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) results in superior survival compared with the adult protocols. Pediatrics-inspired protocols carry an increased risk of toxicity and t...

Feb 26th, 2021 - Asparaginase (Asp) is one of the most important drugs for treating acute lymphoblastic leukemia (ALL). However, off-protocol Asp administration (OPAA) or hypersensitivity may disturb its pharmacokinetic profile. In this retrospective study, we sou...

Feb 26th, 2021 - T-cell acute lymphoblastic leukemia (T-ALL) is characterized by the leukemogenic transformation of immature T-cells, which accumulate an array of genetic and epigenetic lesions, leading to a sustained proliferation of abnormal T cells. Genetic alt...

Feb 26th, 2021 - The unprecedented efficacy of chimeric antigen receptor T (CAR-T) cell immunotherapy of CD19+ B-cell malignancies has opened a new and useful way for the treatment of malignant tumors. Nonetheless, there are still formidable challenges in the fiel...

Feb 25th, 2021 - Autologous chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed/refractory acute lymphoblastic leukemia (r/r ALL). However, certain characteristics of autologous CAR-T cells can delay treatment availability. Rela...

Jan 14th, 2021 - ALL (also called acute lymphocytic leukemia) is an aggressive type of leukemia characterized by the presence of too many lymphoblasts or lymphocytes in the bone marrow and peripheral blood. It can spread to the lymph nodes, spleen, liver, central ...

May 30th, 2020 - Children with Down syndrome and acute lymphoblastic leukemia continue to experience poorer outcomes than children with ALL who do not have Down syndrome, according to study results presented during the ASCO20 Virtual Scientific Program.

May 28th, 2020 - Application of a set of stringent clinical and cytogenetic features as well as minimal residual disease (MRD) criteria can identify a subset of low-risk (LR) pediatric patients with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) who can...

May 12th, 2020 - In pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) who received prior blinatumomab exposure or inotuzumab ozogamicin as bridging therapy, treatment with tisagenlecleucel is associated with consistent ...

Jan 7th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...

Feb 26th, 2021 - The use of pediatrics-inspired protocols in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) results in superior survival compared with the adult protocols. Pediatrics-inspired protocols carry an increased risk of toxicity and t...

Feb 26th, 2021 - Asparaginase (Asp) is one of the most important drugs for treating acute lymphoblastic leukemia (ALL). However, off-protocol Asp administration (OPAA) or hypersensitivity may disturb its pharmacokinetic profile. In this retrospective study, we sou...

Feb 26th, 2021 - T-cell acute lymphoblastic leukemia (T-ALL) is characterized by the leukemogenic transformation of immature T-cells, which accumulate an array of genetic and epigenetic lesions, leading to a sustained proliferation of abnormal T cells. Genetic alt...

Feb 26th, 2021 - The unprecedented efficacy of chimeric antigen receptor T (CAR-T) cell immunotherapy of CD19+ B-cell malignancies has opened a new and useful way for the treatment of malignant tumors. Nonetheless, there are still formidable challenges in the fiel...

Feb 25th, 2021 - Autologous chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed/refractory acute lymphoblastic leukemia (r/r ALL). However, certain characteristics of autologous CAR-T cells can delay treatment availability. Rela...

Feb 2nd, 2021 - For now at least, total body irradiation (TBI) plus etoposide remains the conditioning regimen of choice for children undergoing allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia (ALL), according to an open-label phase...

Jan 14th, 2021 - ALL (also called acute lymphocytic leukemia) is an aggressive type of leukemia characterized by the presence of too many lymphoblasts or lymphocytes in the bone marrow and peripheral blood. It can spread to the lymph nodes, spleen, liver, central ...

Oct 20th, 2020 - The days of using chemotherapy to treat Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) may be numbered. In a phase 2 trial, up-front chemo-free induction/consolidation with the tyrosine kinase inhibitor dasatinib (Sprycel)...

Oct 7th, 2020 - NEW YORK (Reuters Health) - A new guideline from the National Comprehensive Cancer Network (NCCN) provides information about pediatric acute lymphoblastic leukemia (ALL) to patients and their families in an easy-to-learn format. The guideline, bas...

Oct 7th, 2020 - NEW YORK (Reuters Health) - A new guideline from the National Comprehensive Cancer Network (NCCN) provides information about pediatric acute lymphoblastic leukemia (ALL) to patients and their families in an easy-to-learn format. The guideline, bas...